Current topics in microbiology and immunology, Год журнала: 2024, Номер unknown
Опубликована: Янв. 1, 2024
Язык: Английский
Drug Resistance Updates, Год журнала: 2023, Номер 71, С. 100991 - 100991
Опубликована: Июль 31, 2023
Язык: Английский
Процитировано
32
Clinical Microbiology and Infection, Год журнала: 2024, Номер 30(8), С. 999 - 1006
Опубликована: Апрель 24, 2024
Язык: Английский
Процитировано
16
Heliyon, Год журнала: 2024, Номер 10(5), С. e26423 - e26423
Опубликована: Фев. 19, 2024
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and MERS recent decades, underscoring their high potential infectivity humans. Insights from previous have played a significant role developing effective strategies to mitigate the global impact SARS-CoV-2. As January 7, 2024, there been 774,075,242 confirmed cases worldwide. To date, 13.59 billion vaccine doses administered, 7,012,986 documented fatalities (https://www.who.int/)Despite progress addressing rapid evolution SARS-CoV-2 challenges human defenses, presenting ongoing challenges. emergence new lineages, shaped mutation recombination processes, has led successive waves infections. This scenario reveals need for next-generation vaccines as crucial requirement ensuring protection against demand calls formulations that trigger robust adaptive immune response without leading inflammation linked with infection.Key mutations detected Spike protein, critical target neutralizing antibodies design —specifically within Receptor Binding Domain region Omicron variant lineages (B.1.1.529), currently dominant worldwide, intensified concerns due association immunity evasion vaccinations infections.As world deals this evolving threat, narrative extends realm emerging variants, each displaying implications remain largely misunderstood. Notably, JN.1 lineage is gaining prevalence, early findings suggest it stands among immune-evading characteristic attributed its L455S. Moreover, detrimental consequences novel bear particularly on immunocompromised individuals older adults. Immunocompromised face such suboptimal responses vaccines, rendering them more susceptible disease. Similarly, adults an increased risk disease presence comorbid conditions, find themselves at heightened vulnerability develop Thus, recognizing these intricate factors effectively tailoring public health protect vulnerable populations. In context, review aims describe, analyze, discuss current treatments encompassing immunotherapeutic approaches advanced therapies complements will offer solutions counter disadvantages existing options. Preliminary outcomes show virus address immunomodulatory associated COVID-19. Furthermore, capacity promote tissue repair demonstrated, which can be noteworthy who stand actors landscape possess broader potential, offering wide range variants enhancing ability constant virus. are projected treatment alternatives managing Chronic Post-COVID-19 syndromeand long-term complications.
Язык: Английский
Процитировано
10
International Journal of Infectious Diseases, Год журнала: 2024, Номер 144, С. 107046 - 107046
Опубликована: Апрель 12, 2024
ObjectivesTo investigate the effectiveness of intravenous immunoglobulin (IVIG) as treatment for COVID-19 in immunocompromised patients.MethodsThis retrospective study investigated outcomes immunocompromised, vaccine non-responsive, patients that between September 2022 and April 2023 received IVIG region Västerbotten, Sweden. We analyzed clinical data, viral load, anti-SARS-CoV-2 IgG binding neutralization levels patient serum samples production batches. Primary secondary were cure clearance, respectively.ResultsSixteen analyzed. After a median duration four weeks, 60g infusion increased SARS-CoV-2 neutralizing antibody levels, with broad vitro activity against tested variants. The resulted abrogation viremia all general improvement 15 survivors met primary endpoint. Thirteen endpoint at follow-up after months. Two subjects persistent carriage relapsed but successfully retreated IVIG.ConclusionsAntibodies efficiently neutralized several Treatment was associated clearance patients. Our data suggests could be novel alternative this category.
Язык: Английский
Процитировано
10
Communications Biology, Год журнала: 2025, Номер 8(1)
Опубликована: Март 6, 2025
The emergence of various SARS-CoV-2 variants presents challenges for antibody therapeutics, emphasizing the need more potent and broadly neutralizing antibodies. Here, we employed an unbiased screening approach successfully isolated two antibodies from individuals with only exposure to ancestral SARS-CoV-2. One these antibodies, CYFN1006-1, exhibited robust cross-neutralization against a spectrum variants, including latest KP.2, KP.3 XEC, consistent IC50 values ranging ~1 5 ng/mL. It also displayed broad neutralization activity SARS-CoV related sarbecoviruses. Structural analysis revealed that target shared hotspot but mutation-resistant epitopes, their Fabs locking receptor binding domains (RBDs) in "down" conformation through interactions adjacent RBDs, cross-linking Spike trimers into di-trimers. In vivo studies conducted JN.1-infected hamster model validated protective efficacy CYFN1006-1. These findings suggest activities can be identified exclusively virus exposure.
Язык: Английский
Процитировано
2
Annals of Medicine, Год журнала: 2025, Номер 57(1)
Опубликована: Март 26, 2025
This study aimed to identify the optimal strategy for patients with autoimmune diseases by comparing immunoreaction and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines between healthy individuals patients. The PubMed, Embase, Cochrane Library were searched eligible studies on SARS-CoV-2 in published until October 07, 2022. quality each included was evaluated independent reviewers using National Institutes Health assessment tool, STATA 15.0 software used all statistical analyses. A total 84 publications analyzed this meta-analysis, favoring controls regarding serological response (risk ratio, RR=0.88, 95% CI (confidence interval): 0.86-0.91), antibody (RR=0.90, 95%CI: 0.87-0.94), incidence seropositive immunoglobulin G (IgG) (RR=0.74, 0.69-0.80) than post-vaccination. Patients developed lower IgG (standard mean difference, SMD=-0.64 -0.84 -0.43) titer level (SMD=-1.39, -2.30 -0.49) AU/ml. Stratified analyses conducted further according various potential factors full-text studies. who are immunocompromised received more demonstrated poorer humoral responses after vaccination individuals. Despite lack observable favor diseases, trend is close that populations. should be provided a better schedule, considering vaccine subtypes, dose(s), variants concern, immunoassays.
Язык: Английский
Процитировано
1
Опубликована: Апрель 10, 2024
Currently, SARS-CoV-2 has evolved into various variants, including the numerous highly mutated Omicron sub-lineages, significantly increasing immune evasion ability. The development raises concerns about possibly diminished effectiveness of available vaccines and antibody-based therapeutics. Here, we describe those representative categories broadly neutralizing antibodies (bnAbs) that retain prominent against emerging variants sub-lineages. molecular characteristics, epitope conservation, resistance mechanisms these are further detailed, aiming to offer suggestion or direction for therapeutic antibodies, facilitate vaccine design with broad-spectrum potential.
Язык: Английский
Процитировано
7
Journal of Antimicrobial Chemotherapy, Год журнала: 2023, Номер 78(7), С. 1644 - 1648
Опубликована: Май 30, 2023
Abstract Objectives Immunocompromised patients have an increased risk of severe or prolonged COVID-19. Currently available drugs are registered to treat COVID-19 during the first 5 7 days after symptom onset. Data on effectivity in immunocompromised with chronic non-resolving urgently needed. Here, we report outcome treated nirmatrelvir/ritonavir together high-titer convalescent plasma (CP) six Methods persisting (positive PCR Ct values <30 for ≥20 days) received off-label therapy nirmatrelvir/ritonavir. It was combined CP containing BA.5 neutralizing titers ≥1/640 whenever available. Follow-up done by and sequencing nasopharyngeal swabs a weekly basis until viral genome undetectable consecutively. Results Five were One patient monotherapy. Median duration SARS-CoV-2 positivity 70 (range 20–231) before treatment. In four receiving combination therapy, no detected day 14 treatment while monotherapy, value 34 thereafter. Treatment unsuccessful one patient. this patient, did not show protease gene mutations. Conclusions COVID-19, may be effective Larger prospective studies needed confirm these preliminary results should compare different durations.
Язык: Английский
Процитировано
14
Frontiers in Science, Год журнала: 2024, Номер 2
Опубликована: Май 23, 2024
The COVID-19 pandemic accelerated research and innovation across numerous fields of medicine. It emphasized how disease concepts must reflect dynamic heterogeneous interrelationships between physical characteristics, genetics, co-morbidities, environmental exposures, socioeconomic determinants health throughout life. This article explores scientists other stakeholders collaborate in novel, interdisciplinary ways at these new frontiers medicine, focusing on communicable diseases, precision/personalized systems data science. highlighted the critical protective role vaccines against current emerging threats. Radical efficiency gains vaccine development (through mRNA technologies, public private investment, regulatory measures) be leveraged future together with continued area monoclonal antibodies, novel antimicrobials, multisectoral, international action diseases. Inter-individual heterogeneity pathophysiology prompted targeted therapeutics. Beyond COVID-19, medicine will become increasingly personalized via advanced omics-based technologies biology—for example targeting gut microbiome specific mechanisms underlying immunoinflammatory diseases genetic conditions. Modeling proved to strengthening risk assessment supporting decision-making. Advanced computational analytics artificial intelligence (AI) may help integrate epidemic modeling, clinical features, genomics, immune factors, data, anthropometric measures into a “systems medicine” approach. also digital giving telehealth therapeutics roles system resilience patient care. New methods employed during including decentralized trials, could benefit evidence generation decision-making more widely. In conclusion, shaped by multistakeholder collaborations that address complex molecular, clinical, social interrelationships, fostering precision while improving health. Open science, innovative partnerships, patient-centricity key success.
Язык: Английский
Процитировано
6
Viruses, Год журнала: 2024, Номер 16(6), С. 900 - 900
Опубликована: Июнь 1, 2024
Currently, SARS-CoV-2 has evolved into various variants, including the numerous highly mutated Omicron sub-lineages, significantly increasing immune evasion ability. The development raises concerns about possibly diminished effectiveness of available vaccines and antibody-based therapeutics. Here, we describe those representative categories broadly neutralizing antibodies (bnAbs) that retain prominent against emerging variants sub-lineages. molecular characteristics, epitope conservation, resistance mechanisms these are further detailed, aiming to offer suggestion or direction for therapeutic antibodies, facilitate design with broad-spectrum potential.
Язык: Английский
Процитировано
6